Companies don’t plan to fail when it comes to recruitment, but many fail to plan. What happens if your marketing director resigns? A recruiting plan gives your organization the confidence in knowing that whatever happens, there is a process in…
HOME > ORGANIZATION
ORGANIZATION
- Degree of Drug Contribution Increased Most for HIV and AIDS: JHSF Survey
April 13, 2012
- MREAC Seeks to Contact 70 People Who Passed MR Exam through “Transitional Measure”
April 10, 2012
- CMRs Exceed 3000, Rapidly Increasing in Specialty Care: JCSOA
April 6, 2012
- 4 Specific Measures for Distribution Improvement: JPWA President Bessho
March 29, 2012
- JGA Announces GL for Disclosure of Payments to Medical Institutions by Member Companies
March 29, 2012
- JGA Announces Measures to Ensure Stable Supplies of Generic Drugs
March 27, 2012
- JGA to Start Providing Information in July on Out of Stock Generics
March 27, 2012
- NIBIO Offers Clinical Trial Information on Rare Diseases on Website
March 26, 2012
- Growth of Domestic Pharma Industry Will Require Individualized Strategies: FPMAJ Chairman Shoda
March 23, 2012
- IDMA President Doshi Expresses Hopes for Cooperation with Japanese Pharmaceutical Companies
March 21, 2012
- Drugstore Market Reaches ¥5.8 Trillion, 11 Straight Years of Growth: JACDS Survey
March 19, 2012
- Asia Partnership Conference Starts Talks for Early NDA Approval at Inauguration Meeting in Tokyo
March 19, 2012
- JMA “Totally Opposed” to Japan’s Participation in TPP
March 16, 2012
- JPMA Compiles Policies for Transparency in Patient Group Relationships, Disclosure for States of Donations
March 15, 2012
- Wholesale Industry FTC to “Watch Closely” How Drug Makers Respond to Tougher Rules on Business Entertaining
March 7, 2012
- KSLION to Stimulate Innovation in Life Science in Japan: Prof. Y. Natsumeda
March 5, 2012
- Generic Drug Share Reaches 23.6% in 3rd Quarter of FY2011: JGA
March 2, 2012
- EFPIA Japan Chairman Fauchet Says New Committee to Review Health Economic Assessment
March 1, 2012
- Daiichi-Sankyo, Eisai, Pfizer Japan Leaving Strongest Impression at Dispensing Pharmacies: NPhA Survey
February 29, 2012
- JPWA President Bessho Welcomes NPhA’s Efforts for Drug Distribution Improvement
February 29, 2012
ページ
Is policy intervention necessary for Japanese drug makers reliant on off-patent brand-name medicines? Many members of the health ministry’s key…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
The Liberal Democratic Party (LDP) will wrap up its discussions on the FY2023 tax reform plan within a few days. Some provisions of the R&D tax credit system, which allow drug makers to deduct a portion of R&D expenses from…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…